-
1 Comment
Camurus AB (publ) is currently in a long term uptrend where the price is trading 11.3% above its 200 day moving average.
From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 41.4.
Camurus AB (publ)'s total revenue rose by 186.3% to $100M since the same quarter in the previous year.
Its net income has increased by 71.8% to $-20M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.8% to $-73M since the same quarter in the previous year.
Based on the above factors, Camurus AB (publ) gets an overall score of 5/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | SE0007692850 |
| Market Cap | 3B |
|---|---|
| PE Ratio | 80.23 |
| Target Price | None |
| Beta | 0.86 |
| Dividend Yield | None |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 7CA.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
